Clinical trialNCT03402659CompletedPhase 2Interventional

Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease

SponsorEIP Pharma IncEnrollment161Alzheimer Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase 2b, double-blind, placebo controlled proof-of-concept study of a an oral small molecule selective inhibitor of p38 alpha kinase, neflamapimod, administered for 24 weeks in subjects with mild Alzheimer's disease. The primary objective is to demonstrate significant improvement relative to placebo-treatment in episodic memory function, as assessed by the Hopkins Verbal Learning Test. Secondary endpoints include Clinical Dementia Rating scale (CDR), Wechsler Memory Scale (WMS), Mini-Mental-Status-Examination (MMSE) and Cerebrospinal fluid (CSF) biomarkers of AD disease activity and progression.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

John Alam, MD
EIP Pharma
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

38 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Czechia

Neuro Hk, S.R.O. Poliklinika Choceň, A.S.
Choceň, Czechia
Cerebrovaskulární Poradna S.R.O.
Moravská Ostrava, Czechia
Clintrial S.R.O
Prague, Czechia
Private Psychiatric Centre
Prague, Czechia
Vestra Clinics S.R.O
Rychnov nad Kněžnou, Czechia

Denmark

Ccbr Clinical Research, Aalborg
Aalborg, Denmark
Ccbr Clinical Research, Ballerup
Ballerup Municipality, Denmark
Ccbr Clinical Research, Vejle
Vejle, Denmark

Netherlands

Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
Alzheimer Research Center
Amsterdam, Netherlands
Amphia Ziekhuis
Breda, Netherlands

United Kingdom

Mac Clinical Research Tankersley
Barnsley, United Kingdom
Re:cognition Health Birmingham
Birmingham, United Kingdom
Mac Clinical Research Blackpool
Blackpool, United Kingdom
Fulbourn Hospital
Cambridge, United Kingdom
Mac Clinical Research Leeds
Leeds, United Kingdom
Mac Clinical Research Liverpool
Liverpool, United Kingdom
Re:cognition Health London
London, United Kingdom
St. Pancras Clinical Research
London, United Kingdom
Mac Clinical Research Manchester
Manchester, United Kingdom
Re:cognition Health Plymouth
Plymouth, United Kingdom
5 Boroughs/north West Boroughs Healthcare Nhs Foundation Trust
Warrington, United Kingdom

United States

Alliance for Research
Long Beach, California, United States
Pacific Research Network
San Diego, California, United States
Citrials
Santa Ana, California, United States
Southern California Research, Llc
Simi Valley, California, United States
Viking Clinical Research
Temecula, California, United States
Miami Dade Medical Research Institute
Miami, Florida, United States
Sensible Healthcare, Llc
Ocoee, Florida, United States
Anchor Neuroscience
Pensacola, Florida, United States
Progressive Medical Research
Port Orange, Florida, United States
Suncoast Neuroscience Associates, Inc.
St. Petersburg, Florida, United States
Florida Premier Research Institute
Winter Park, Florida, United States
Northwest Clinical Trials
Boise, Idaho, United States
Massgeneral Institute for Neurodegenerative Disease
Charlestown, Massachusetts, United States
Manhattan Behavioral Medicine
New York, New York, United States
Alzheimer'S Memory Center and Research Institute
Charlotte, North Carolina, United States
Northwest Clinical Research Center
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Neflamapimod

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Dec 2017
Primary completion: 30 Jun 2019
Completion: 31 Jul 2019
Last update posted: 27 Oct 2021
Registered enrollment: 161
Registry id: NCT03402659

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.